Probucol
From Wikipedia, the free encyclopedia
|
Probucol
|
|
| Systematic (IUPAC) name | |
| 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl) sulfanylpropan-2-ylsulfanyl]phenol | |
| Identifiers | |
| CAS number | |
| ATC code | C10 |
| PubChem | |
| Chemical data | |
| Formula | C31H48O2S2 |
| Mol. mass | 516.844 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease. However, clinical trials were stopped after it was found that it causes Long QT syndrome in patients.
[edit] Mechanism
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption [1]. Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.
[edit] References
|
||||||||||||||||||||||||||

